Clinical Proteomics – Ready for Prime Time in Urological Cancer Diagnostics?
Eric Schiffer, Mosaiques Diagnostics, Clinical Project Manager, speaking at Cancer Proteomics 2010.
Application of Profiling the Antibody Repertoire for Discovery of Cancer Biomarkers.
Delores Cahill, University College Dublin, Professor, speaking at Cancer Proteomics 2010.
13CO2 a Biomarker in Breath for Individualized Cancer Therapy
Anil Modak, Cambridge Isotope Laboratory, Associate Director, speaking at Cancer Proteomics 2010.
The Foundation of the NIH (FNIH) Biomarkers Consortium Builds Consensus Through Public Private Partnerships
Maria Vassileva, Scientific Program Manager, Foundation for the National Institutes of Health, speaking at European Biomarkers Summit 2009
Industry Snapshot: Cancer Personalized Medicine Market Landscape
Enal Razvi, Biotechnology Analyst, Select Biosciences, speaking at European Biomarkers Summit 2009
Genetic Polymorphisms Associated to Adverse Reactions to 5-FU or Capecitabine in Colorectal Cancer Patients
Luis Lopez-Fernandez, Lab Director, Hospital General Universitario Gregorio Marañon, speaking at European Biomarkers Summit 2009
Biomarker Qualification: Europe is ready, are you?
Patricia Hurley, Division Head, ERA Consulting, speaking at European Biomarkers Summit 2009
Lessons Learned From HTS: The Short and Long Journey to Probe Discovery
Hakim Djaballah, Director, Memorial Sloan Kettering Cancer Center, speaking at Probe Discovery 2009
Lead-discovery and Probe Development in Smaller Academic-based HTS Labs
Andy Mesecar, Professor, University of Illinois, speaking at Probe Discovery 2009